FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems

Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems

Drug Test

February 20, 2025

By AdminPrabadin - 2 months ago

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems

AdminPrabadin

administrator

Email

Call us

FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid

FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis

Related Articles

Artrifan King may be harmful due to hidden…

Anesthetic and Analgesic Drug Products Advisory Committee Roster

Drug Safety and Risk Management Advisory Committee Roster

Leave a Reply Cancel reply